Kyungpook National University Industry-academic Cooperation Foundation

Seoul National University

Yonsei University

Industry-university Cooperation Foundation Hanyang University

Gwangju Institute of Science and Technology

Samsung Life Public Welfare Foundation

Iucf-hyu

Hee Kyung Jin

Min Hee Park

Jae Sung Bae

Jae-Sung Bae

Ju Youn Lee

Seung Hoon Han

Seung Hyun Kim

Min Jae Lee

Hye Jin Lim

Myung Shik Lee

Jin Hee Ahn

Chang-Seok Ki

Haushabhau Shivaji Pagire

Jong Kil Lee

The present invention relates to a composition for preventing or treating neurodegenerative diseases or depression, containing a 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative as an active ingredient and more specifically, to a pharmaceutical composition for preventing or treating neurodegenerative diseases or depression, containing, as an active ingredient, the compound having an effect of directly inhibiting ASM activity.

2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative of novel compound for directly inhibiting ASM activity, and use thereof

The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising a COX2 acetylating agent as an active ingredient and, more particularly, to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising, as an active ingredient, a COX2 acetylating agent which exhibits an effect of inhibiting the deposition of amyloid-β in brain neurons, reducing excessive neuroinflammatory responses, and increasing the phagocytosis of amyloid-β in microglial cells. The pharmaceutical composition for preventing or treating neurodegenerative diseases comprising the COX2 acetylating agent as an active ingredient has the effects of alleviating neuroinflammation by promoting COX2 acetylation in neurons and secreting specialized pro-resolving mediators (SPMs) and thus, can be very useful in the development of a preventive or therapeutic agent for neurodegenerative diseases.

Pharmaceutical composition for preventing or treating neurodegenerative diseases comprising COX2 acetylating agent as active ingredient

A composition for diagnosing diseases associated with COX2 overexpression, containing a compound with a structural feature of exhibiting strong binding activity to a COX2 protein; and a screening method therefor.

Composition for diagnosing diseases associated with COX2 overexpression and screening method therefor

The present invention relates to a composition for diagnosis of degenerative neurological diseases and, more specifically, to a composition for diagnosis of degenerative neurological diseases, comprising an agent for measuring the level of acetylation of COX2. According to the present invention, since acetylation of COX2 in degenerative neurological diseases is significantly reduced, whether COX2 is acetylated may be utilized as a diagnostic marker for degenerative neurological diseases, and it is possible to diagnose degenerative neurological diseases more rapidly and accurately by using same.

Composition for diagnosis of degenerative neurological diseases

The present invention relates to a novel use for HDL-ApoM-S1P (a high density lipoprotein in which apolipoprotein M is impregnated with sphingosine-1-phosphate), and more particularly, to using HDL-ApoM-S1P to prevent, improve, or treat degenerative brain disorders (in particular, Alzheimer's disease), cognitive disorders, learning disabilities, and memory disorders, and using HDL-ApoM-S1P to improve cognitive ability, learning ability, and memory. The HDL-ApoM-S1P according to the present invention not only alleviates neuroinflammation but also significantly exhibits improvement effects of cognitive disorder, learning disability, and memory disorder with respect to individuals suffering from degenerative brain disorders (in particular, Alzheimer's disease), and exhibits an effect of greatly reducing amyloid beta and tau deposition. Moreover, increased HDL-ApoM-S1P in the body also has an excellent effect of improving the cognitive, learning, and memory abilities of non-disabled individuals.

Pharmaceutical composition for preventing or treating degenerative brain disorders including HDL-APOM-S1P as active ingredient

The present invention relates to a amyotrophic lateral sclerosis (ALS) diagnostic composition using acid sphingomyelinase (ASM), and a method for detecting diagnostic markers and, more specifically, to a method and a composition for detecting markers for ALS, the method comprising the steps of: (a) providing a sample of a subject; (b) measuring the ASM expression level or the enzyme activation level in the sample; (c) determining that a subject, of which the ASM expression level or the enzyme activation level is increased compared to that of a normal person, has ALS. According to the investigation of the present inventors, the activity of ASM, among lipids and enzymes related to the sphingolipid metabolism, is specifically increased in a sample of an ALS patient compared to that of a normal person. ASM can be used as a marker for diagnosing ALS, thereby enabling the development of a novel and effective diagnostic reagent.

Amyotrophic lateral sclerosis diagnostic composition using acid sphingomyelinase, and method for detecting diagnostic markers

The present invention relates to a novel phenylsulfonyl oxazole derivative and a use thereof and specifically, to a compound represented by Chemical Formula 1 in the present specification or a pharmaceutically acceptable salt thereof, and to a use thereof for prevention, treatment, or improvement of neurodegenerative disease.

Phenylsulfonyl oxazole derivative and use thereof

The present invention relates to a novel peptide exhibiting an effect of releasing myelopoiesis stem cells into blood and an osteoporosis therapeutic effect and use thereof and, in particularly, to a novel peptide consisting of an amino acid sequence of SEQ. ID.NO:1 which has effects of releasing hematopoietic stem cells into a bloodstream and decreasing osteoclast cells in bone narrow, and a pharmaceutical composition comprising the novel peptide as an active ingredient for preventing or treating neutropenia, anemia or osteoporosis. Because of side effects, the peptide of the present invention not only increases level of leukocytes, red blood cells and platelets in blood, but also alleviates a decrease in bone density, and therefore, can be very usefully used for the development of a prophylactic or therapeutic agent for neutropenia, anemia or osteoporosis.

Neuropeptide Y fragment capable of releasing hematopoietic stem cells into blood and treating osteoporosis

The present invention relates to a method for treating degenerative neurological disorders in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an acid sphingomyelinase (ASM) activity inhibitor or expression inhibitor as an active ingredient.

Method for treating a neurological disorder comprising administering ASM inhibitors

The present invention relates to a pharmaceutical composition containing stem cells in which vascular endothelial growth factor (VEGF) is overexpressed as an effective ingredient for preventing or treating neurodegenerative diseases. The stem cells in which VEGF is overexpressed according to the present invention effectively act against the neurodegenerative disease-induced VEGF reduction of neural stem cells in the SVC to inhibit the abnormal migration of neural stem cells, suppress inflammatory responses, and restrain the accumulation of cholesterol and spingolipids in the cerebral cortex, thus restoring the behavior exercise capacity of animal models, whereby the pharmaceutical composition can be used as an effective therapeutic agent for neurodegenerative diseases.

Pharmaceutical composition containing stem cell in which vascular endothelial growth factor is overexpressed as effective ingredient for preventing or treating neurodegenerative disease

Method for treating a degenerative neurological disorders comprising administering ASM inhibitor

Provided is a composition containing neuropeptide Y for inhibiting side effects of anticancer agents. The neuropeptide Y of the present invention exhibits an effect of mitigating side effects, especially bone marrow injury and neurological disorders, occurring due to the administration of anticancer agents, and thus may be useful as an anticancer adjuvant which may mitigate side effects of anticancer agents and enhance the effect of anticancer agents.

Composition containing neuropeptide Y for inhibiting side effects of anticancer agents

The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 16 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.

Peptides for treating bone diseases and use thereof

There is provided a method for treating or reducing an anticancer agent-induced nephrotoxic injury, the method comprising the step of administering a Y1 receptor activator in an amount effective to treat or reduce the anticancer agent-induced nephrotoxic injury in a subject. Further, there is provided a method for screening an agent for treating or reducing an anticancer agent-induced nephrotoxic injury, the method comprising (a) applying a candidate material to a test sample of renal tissues or cells; and (b) identifying a Y1 receptor signaling in the test sample of renal tissues or cells.

Growing community of inventors

Daegu, South Korea

Hee Kyung Jin